Results of an international comparison for the activity measurement of 177Lu

Zimmerman, Brian E.; Altzitzoglou, T.; Antohe, Andrei; Arinc, A; Bakhshandeiar, E; Bergeron, Denis E.; Bignell, L.J.; Bobin, Christophe; Capogni, M.; Cessna, Jeffrey T.; Cozzella, M.L.; Silva, C J da; Felice, P. De; Dias, Mauro S.; Dziel, Tomasz; Fazio, A.; Fitzgerald, R.; Iwahara, Akira; Jaubert, F.; Johansson, Lena; Keightley, J D; Koskinas, Marina F.; Kossert, Karsten; Lubbe, J.; Luca, A.; Li, Mo; Nähle, O.; Ott, Oliver J.; Paepen, J.; Pommé, S.; Sahagia, Maria; Simpson, B.R.S.; Silva, F F; Ammel, R. Van; Staden, M.J. van; Wyngaardt, W.M. van; Yamazaki, Ione M.

doi:10.1016/j.apradiso.2012.02.014

Cited by 17 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The source was delivered in a 10 mL Schott-type dose vial and NIST performed measurements on multiple dose calibrators in both the dose vial and 5 mL ampoule geometries. The standard activity was taken from ICA using the K -value determined in 2009 by anticoincidence counting [32]. The uncertainty on the standard activity (0.37 %) was the largest component in the combined standard uncertainties on the determined DSs in all cases except for the CRC-35R calibrator where the uncertainty on the reading (estimated in this case from the range of minimum and maximum readings observed over a few seconds) was larger.…”

Section: Resultsmentioning

confidence: 99%

An update on ‘dose calibrator’ settings for nuclides used in nuclear medicine

Bergeron

Cessna

2018

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

An update on ‘dose calibrator’ settings for nuclides used in nuclear medicine

Bergeron

Cessna

2018

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…In Zimmerman et al (15), the amount of 177m Lu was estimated to approximately 0.03% of the 177 Lu at a nominal reference time, thus giving an x value of 0.9997. In the present work, x was measured to 0.9997. x values of 0.9995 and 0.99975 were thus assumed in further analyses, representative of 1 worst case and 1 more likely scenario.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Retention of ¹⁷⁷Lu/^177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging

et al. 2015

View full text Add to dashboard Cite

Dosimetry in peptide receptor radionuclide therapy using 177 Lu-DOTATATE is based on patient imaging during the first week after administration and determination of the activity retention as a function of time for different tissues. For calculation of the absorbed dose, it is generally assumed that the long-term activity retention follows the pattern determined from the first week. This work aimed to investigate the validity of this assumption by performing additional patient measurements between 5 and 10 wk after administration. A further aim was to investigate to what extent absorbed dose values were affected when including these measurements, also taking into account the radionuclide impurity of 177m Lu and build-up of secondary 177 Lu from the 177m Lu decay. Methods: A combination of methods was used: planar g-camera imaging as part of the clinical dosimetry protocol, determination of the whole-body activity between 5 and 9 wk after injection using spectrometric NaI(Tl) and HPGe detectors, and imaging between 5 and 10 wk after injection for assessment of the activity distribution. From these measurements the long-term retention of activity was determined and the relative influence on absorbed doses calculated. Results: The most important finding was a clearly visualized tumor uptake in images from between 5 and 7 wk after injection and in 1 patient also kidney and spleen uptake in images acquired on day 33. As a consequence, the total-body time-activity curve had a tail, which was not completely captured by imaging during the first week. The absorbed doses to total body and tumors obtained when including these late time points were on average 5%-6% higher than those obtained when using data acquired during the first week. The contributions to the absorbed dose from 177m Lu and secondary 177 Lu were negligible. Conclusion: At approximately 5-7 wk after injection, there was a measureable amount of 177 Lu-DOTATATE in patients, which is mainly governed by retention in tumors. For tumor dosimetry, imaging at a later time than the routinely used 7 d may be warranted. The contribution to the absorbed dose from the radionuclide impurity of 177m Lu was negligible.

show abstract

“…As the very first step, traceability of the activity meter used for measurement of 177 Lu is established by cross-calibration with a standard metrology laboratory (Zimmerman et al , 2012). In this example, a traceable secondary standard dose calibrator (Southern Scientific, Henfield, UK) is used, which comes with a traceability certificate issued by the National Physical Laboratory (Teddington, UK).…”

Section: A1 131i Nai Treatment Of Benign Thyroid Diseasementioning

confidence: 99%

ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy

et al. 2021

View full text Add to dashboard Cite

The Commission wishes to express its appreciation to the individuals involved in the preparation of this Report for the time and efforts that they devoted to this task and to express its appreciation to the organizations with which they are affiliated.All rights reserved. No part of this book may be reproduced, stored in retrieval systems or transmitted in any form by any means, electronic, electrostatic, magnetic, mechanical photocopying, recording or otherwise, without the permission in writing from the publishers.

show abstract

Results of an international comparison for the activity measurement of 177Lu

Cited by 17 publications

References 11 publications

An update on ‘dose calibrator’ settings for nuclides used in nuclear medicine

An update on ‘dose calibrator’ settings for nuclides used in nuclear medicine

Long-Term Retention of ¹⁷⁷Lu/^177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging

ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy

Contact Info

Product

Resources

About

Results of an international comparison for the activity measurement of 177Lu

Cited by 17 publications

References 11 publications

An update on ‘dose calibrator’ settings for nuclides used in nuclear medicine

An update on ‘dose calibrator’ settings for nuclides used in nuclear medicine

Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging

ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy

Contact Info

Product

Resources

About

Long-Term Retention of ¹⁷⁷Lu/^177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging